Oropharyngeal Cancer and HPV: Diagnosis, Staging and Prognosis

Oropharynx: soft palate (superior), base of tongue (inferior), palatine tonsils (lateral walls), posterior pharyngeal wall. The lymphoid Waldeyer's ring is dense here. This tissue richness is HPV's primary entry niche.

Historically oropharyngeal cancer was a smoking/alcohol cancer — male, 50-70 years, years of heavy tobacco/alcohol. Over the past 20 years HPV-related forms have markedly risen — younger (40-60 years), male-dominant, little or no tobacco/alcohol, higher socioeconomic status, oral-sex transmission.

HPV-16 is the main agent: >90% of HPV+ oropharyngeal cancers; HPV-18 and other high-risk types (31, 33, 35) small fractions. HPV-16 inactivates retinoblastoma (Rb) and p53 tumour suppressors → uncontrolled proliferation. Tonsillar and base-of-tongue crypts are favoured.

Historical context: pre-2000 oropharyngeal cancer was 15-25% HPV+; in the 2020s, in developed countries 70-80% HPV+. In the US, Australia, Scandinavia, HPV+ oropharyngeal is now the most common head & neck cancer. In Turkey the proportion is lower (30-50% — regional variation) but rising.

HPV+ vs HPV- biology: HPV+ — p16 overexpression (IHC marker), genomically fewer mutations (rare 9p21 deletion, rare p53 mutation, rare EGFR amplification), basaloid morphology tendency, deep crypt localisation. HPV- — TP53 mutation, CDKN2A deletion, more invasive clinical behaviour.

Clinical differences: HPV+ — small primary but large neck nodes (classic "occult primary") — patients present with a neck mass and primary is detected later. HPV- — earlier primary symptoms, smaller nodes.

Prognosis differences: HPV+ 5-year survival 80-90%; HPV- 50-60%. The gap reflects better treatment response (radio- and chemo-sensitive) + biological behaviour. AJCC 8th edition introduced two separate staging systems accordingly. Related overview: our head and neck cancer surgery programme.

Most common presentation: neck mass (typically level II, III; unilateral). In HPV+ the primary may be small and elusive — sometimes "occult primary" — primary is searched after a neck mass. Painless mass may initially be mistaken for infection; if 2-3 weeks of antibiotics fail, malignancy workup.

Other symptoms: dysphagia (especially solids), foreign body sensation, referred ear pain (otalgia — glossopharyngeal), voice change (late stage, laryngeal extension), tonsillar asymmetry (enlargement, ulceration), trismus (lateral, masticatory muscle involvement), weight loss, blood-streaked saliva.

Risk factor enquiry: sexual behaviour (oral sex; HPV+ link), smoking and alcohol (major for HPV-), family history, occupational exposure (formaldehyde, nickel), immunosuppression (HIV, transplant), oral hygiene.

Examination: full head and neck exam — direct oropharyngeal view, palpation (base of tongue, tonsils), nasopharynx and hypopharynx visual or flexible endoscope, neck node palpation (levels II-V), cranial nerve examination (V, IX, X, XI, XII).

Biopsy: direct tonsillectomy or base-of-tongue biopsy (under general anaesthesia) for primary diagnosis. Neck mass — fine needle aspiration (FNA) cytology.

p16/HPV testing: mandatory for all oropharyngeal SCC. p16 immunohistochemistry — high sensitivity and specificity (>95%). Positive p16 confirmed by HPV DNA in-situ hybridisation or HPV PCR.

Imaging: contrast-enhanced CT or MRI (primary + neck nodes), chest CT (metastasis screen), PET-CT (especially occult primary or advanced stage whole-body scan).

Staging: AJCC 8 — separate for HPV+ (small T, large N typically downstaged) and HPV-. Clinical (cTNM), pathologic (pTNM, post-surgery) and indicative (ypTNM, post-neoadjuvant) staging.

Early stage (T1-2 N0-1, HPV+): single-modality preferred. Surgery (TORS — Transoral Robotic Surgery, ideal for tonsil and base of tongue; transoral laser microsurgery alternative) + selective neck dissection. Alternative: definitive radiotherapy (66-70 Gy, IMRT). Similar oncologic outcomes.

TORS pros: minimally invasive, good functional outcome (swallowing, voice), short hospital stay, avoids long-term chemoradiotherapy effects (xerostomia, fibrosis, dysphagia); adjuvant therapy may be needed by pathology.

Radiotherapy (RT/CRT) pros: organ-preserving without surgery, treats wide anatomic field including neck in a single course, no surgical morbidity (RLN, ECA injury). Cons: 6-7 weeks daily treatment, acute toxicity (mucositis, xerostomia, dermatitis), long-term (fibrosis, dysphagia, hypothyroidism, osteoradionecrosis).

Advanced stage (T3-4 or N2-3): combined modality. Traditional: definitive chemoradiotherapy (cisplatin + radiotherapy) — organ-preserving standard. Alternative: radical surgery (head & neck — large resection + neck dissection, reconstruction) + adjuvant chemoradiotherapy.

Chemotherapy: cisplatin (high-dose 100 mg/m² q3w or weekly 40 mg/m²) standard. Cisplatin-unfit (renal, hearing): carboplatin/5-FU, cetuximab. Cisplatin radiosensitises + systemic antitumour effect.

Adjuvant by pathology (post-surgery): high risk (positive margin, extracapsular nodal extension) → chemoradiotherapy; intermediate (multiple nodes, perineural invasion, lymphovascular invasion, T3-4) → radiotherapy; low risk (T1-2 N0-1, clean margin, no ECE, no additional risk) → observation or selected RT.

De-escalation research: HPV+'s better prognosis prompts "less treatment, same outcome" trials. Studies: lower-dose RT (60 Gy → 50-54 Gy), cisplatin replaced with cetuximab (NRG-HN002, RTOG 1016 — failed, cisplatin superior), reducing adjuvant. Current evidence: cisplatin remains chemo of choice; de-escalation only in trials. Routine de-escalation outside trials is not recommended. Step-by-step details: head and neck cancer symptoms.

TORS — transoral robotic resection of oropharyngeal tumours using the daVinci system. FDA approved 2009; now the standard surgical approach for HPV+ oropharyngeal cancer.

Indications: T1-T2 oropharyngeal SCC (tonsil or base of tongue), selected T3 (when structure-sparing resection is possible). Anatomic accessibility is critical — small trismus, small tongue, high base of tongue, limited mouth opening can preclude.

Procedure: patient supine; sequential mouth gag (Crowe-Davis, FK retractor) then daVinci 3-4 arms (camera + 2-3 instrument arms). 3D high-resolution view, ergonomic instrument motion. Tumour resected en bloc; intraoperative frozen sections may be used for margins.

Neck dissection: TORS combined with selective neck dissection (levels II-IV, sometimes IB) concurrently or staged. Nodal sampling is essential for tumour biology and adjuvant decision.

Postoperative: average hospital stay 3-5 days. Nasogastric tube feeding initially; oral feeding begins within 1-2 weeks. Voice returns early, swallowing rehab with SLP.

Outcomes: 85-95% 5-year overall survival in HPV+; functionally 85%+ return to normal diet, voice/speech preserved, xerostomia far less than chemoradiotherapy.

Complications: bleeding (postop 1-2 weeks — pharyngeal/carotid territory, can be severe — hospital monitoring), trismus, transient dysphagia, taste change, oro-cervical fistula (rare). Mortality <1%.

Adjuvant decision after TORS: pT1-T2, clean margin, no ECE, N0-N1 → observation or selected RT; positive margin or ECE → chemoradiotherapy; multiple nodes (N2), perineural/lymphovascular invasion → RT.

Acute RT/CRT side effects: mucositis (oral and pharyngeal — painful swallowing, nutrition issue), taste change, xerostomia (salivary radiation damage), dermatitis (skin burn), nausea/vomiting (cisplatin), neutropenia/anaemia, oto- and nephrotoxicity (cisplatin), fatigue. Management: pain control (including opioids), nutrition support (gastrostomy — PEG, often needed), antiemetics, hydration, GMSF (if needed).

Long-term effects: xerostomia (gland atrophy, permanent or partially recoverable), dysphagia (fibrosis, pharyngeal muscle weakness), trismus (masticatory fibrosis), taste change (years), hypothyroidism (25-50% with neck RT — annual TSH), osteoradionecrosis (especially mandible — after dental extraction), carotid stenosis (long-term — stroke risk), second malignancy (in RT field).

Dental and oral health: pre-RT full dental review, necessary extractions (prevent osteoradionecrosis), lifelong fluoride therapy. No extractions for 3 months post-RT — osteoradionecrosis trigger. Lifelong annual dental review.

Swallowing rehab: SLP-led. "Swallowing exercises" started before RT reduce dysphagia (proactive approach). Post-RT exercises (Mendelsohn, effortful swallow, Shaker), electrostimulation, video fluoroscopy guidance.

Nutrition: PEG often needed during and after treatment; preventing severe weight loss (5-15% loss typical in CRT). Dietitian support.

Psychosocial support: diagnosis shock, treatment duration, functional impact (eating, speech, face), sexual health (HPV context), partner relationship, career — psychology and social work support. Support groups helpful.

Follow-up: first 2 years every 3 months, next 3 years every 6 months, then annual. Includes: examination, imaging (PET-CT at 3 months, then MRI/CT), TSH, thyroglobulin assessment, second primary screening (particularly if smoking history).

Prognostic message: HPV+ oropharyngeal cancer is now the most treatable head & neck cancer group — 5-year survival 80-90%. Early diagnosis + multidisciplinary team + individualised treatment + lifestyle (smoking cessation, alcohol moderation, dental care) substantially improves outcomes. Related reading: our multidisciplinary tumour board.